ATR 1072

San Diego–based Atrium Therapeutics launched as a publicly traded biotechnology company (Nasdaq: RNA) with approximately USD 270 million in cash to develop RNA therapeutics for rare genetic cardiomyopathies. The company was created as a spinoff tied to Novartis’ acquisition of Avidity Biosciences, with Atrium emerging as an independent entity focused on cardiac applications of RNA medicines. Unlike a traditional venture-backed biotech launch, Atrium’s initial capital base was allocated through the corporate transaction that formed the company. The funding will support advancement of two lead candidates through IND-enabling studies, manufacturing development, and early clinical trials, alongside additional undisclosed research-stage programs. Atrium’s pipeline centers on two RNA-based therapies targeting rare inherited heart diseases. ATR-1072 is being developed for PRKAG2 syndrome, a genetic cardiomyopathy caused by mutations that increase activity of AMP-activated protein kinase (AMPK). The resulting glycogen accumulation in heart cells can lead to cardiac hypertrophy, arrhythmias, and conduction abnormalities. The company estimates 1,000–2,000 patients in the United States may have the disorder. IND-enabling studies and manufacturing work are underway, with an FDA IND filing expected in H2 2026. ATR-1086 targets phospholamban (PLN) cardiomyopathy, a progressive condition driven by mutations affecting regulation of the SERCA2a calcium pump in cardiomyocytes. The disease can lead to dilated or arrhythmogenic cardiomyopathy and carries a significant risk of heart failure and sudden cardiac death. Atrium estimates 2,000–4,000 affected individuals in the United States. Preclinical studies are expected to begin in 2026, with a potential IND submission in 2027. Both programs remain in the pre-IND stage, and no clinical trials have yet been registered publicly. Atrium’s technology originates from Avidity Biosciences, which developed an antibody-oligonucleotide conjugate (AOC) platform. The approach links a monoclonal antibody targeting a tissue-specific receptor with an oligonucleotide payload, enabling targeted delivery of RNA therapeutics outside the liver. Avidity previously validated this strategy in skeletal muscle for diseases such as Duchenne muscular dystrophy and myotonic dystrophy. Atrium is applying a related concept to deliver siRNA therapies to cardiac tissue, with the aim of selectively silencing disease-causing genes in cardiomyocytes. If successful, the approach could offer advantages over viral gene therapies, including repeat dosing and reversible gene silencing. However, targeted RNA delivery to the heart remains clinically unproven. Atrium is led by President and CEO Kathleen Gallagher, while Sarah Boyce, former CEO of Avidity Biosciences, serves as chair of the board. The company begins operations with two clinical candidates in development, additional research programs, and a platform aimed at expanding RNA medicines into precision cardiology. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

近日，AOC先驱Avidity Biosciences旗下子公司Atrium Therapeutics宣布正式成立，并获得了约2.7亿美元的启动资金。 这笔资金并非来自外部投资者或风险投资基金，而是完全由其母公司Avidity提供，同时，这笔注资也是当初诺华收购Avidity时所提出的交易条件之一。 来自诺华的担保 Atrium是一家非常年轻的Biotech公司，从注册成立（2025年9月）至今仅有约5个月的时间，公司的研发方向主要聚焦在心脏疾病的RNA疗法领域。 Atrium的诞生主要源自一起120亿美元的收购案。在去年10月，诺华与Avidity达成了最终合并协议，诺华以每股72美元/股现金收购Avidity，收购总价为120亿美元。而这笔收购并不包含Avidity旗下的所有资产，当时，诺华只想要Avidity的神经科学项目（已进入临床阶段），不想要早期心脏病学项目。 而将心脏病学业务分拆为独立公司并注资，便是当初诺华收购Avidity时向其所提出的交易条件之一，并且诺华还为这笔注资做了担保，如果Avidity账户资金不足以支付2.7亿美元，诺华将来补足这个差额。 在该笔收购交易完成前，Avidity很快就注册成立了这家新成立的全资子公司（SpinCo）——Atrium，承接Avidity的心脏病学项目及相关合作业务，当时，Avidity的首席项目官（CPO）也被任命来负责分拆的工作，现已担任了该公司的总裁兼首席执行官。 母公司的托举 Atrium能快速推出也离不开Avidity各方面的托举。根据分拆规划，Atrium将继承Avidity旗下的两个早期心脏病项目ATR 1072和ATR 1086、clinically validated RNA递送平台以及与BMS、Lilly的相关合作业务。 目前，Atrium有四个开发项目，均处于临床前阶段，ATR 1072和ATR 1086是Atrium推进的最主要的两条管线，前者被开发用于治疗PRKAG2综合征，目前处于IND-enabling阶段，公司计划在2026年下半年提交IND。ATR 1086则是针对PLN心肌病，预计在2027年提交IND。管线中，还有两个未公开的研究项目。 而除了管线、技术平台以及合作关系外，Atrium还完全继承了Avidity在纳斯达克的上市地位，不仅包括其上市资格，还包括其股票代码以及原有股东（每持有10股Avidity股票，可获得1股Atrium股票）。现在，Atrium已正式作为独立上市公司开始交易。 参考出处： https://www.sec.gov/Archives/edgar/data/2093101/000119312525314415/d42675dex991.htm https://www.prnewswire.com/news-releases/atrium-therapeutics-launches-with-approximately-270-million-to-advance-novel-rna-medicines-for-rare-genetic-cardiomyopathies-302699662.html#:~:text=Atrium%20Therapeutics%2C%20Inc.%20%28Nasdaq%3A%20RNA%29%20is%20pioneering%20targeted,standard%20of%20care%20for%20people%20living%20with%20cardiomyopathies. https://www.fiercebiotech.com/biotech/atrium-arises-novartis-avidity-buy-270-million-and-pair-preclinical-cardio-candidates